Objectives: To conduct an economic evaluation of the currently prescribed treatments for
stroke prevention in patients with non-valvular atrial fibrillation (NVAF) including warfarin …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …

Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …

Objective Our objective was to assess the cost effectiveness of apixaban versus edoxaban
in the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) …

Background Warfarin, an inexpensive drug that has been available for over half a century,
has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …